$126.16
1.79% yesterday
Nasdaq, Sep 12, 10:00 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Stock price

$126.16
+12.83 11.32% 1M
-8.00 5.96% 6M
+3.01 2.44% YTD
+19.71 18.52% 1Y
-26.71 17.47% 3Y
-14.25 10.15% 5Y
-32.24 20.35% 10Y
+108.43 611.56% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-2.30 1.79%

Key metrics

Basic
Market capitalization
$7.7b
Enterprise Value
$11.3b
Net debt
$3.7b
Cash
$1.7b
Shares outstanding
60.6m
Valuation (TTM | estimate)
P/E
negative | 23.6
P/S
1.9 | 1.8
EV/Sales
2.8 | 2.6
EV/FCF
9.2
P/B
2.1
Financial Health
Equity Ratio
34.1%
Return on Equity
13.7%
ROCE
6.9%
ROIC
5.3%
Debt/Equity
1.4
Financials (TTM | estimate)
Revenue
$4.1b | $4.3b
EBITDA
$1.2b | $786.6m
EBIT
$614.1m | $751.1m
Net Income
$-404.8m | $324.4m
Free Cash Flow
$1.2b
Growth (TTM | estimate)
Revenue
4.5% | 5.7%
EBITDA
1.1% | -41.9%
EBIT
-0.3% | 3.4%
Net Income
-202.5% | -42.1%
Free Cash Flow
22.0%
Margin (TTM | estimate)
Gross
88.7%
EBITDA
30.5% | 18.3%
EBIT
15.0%
Net
-9.9% | 7.6%
Free Cash Flow
30.3%
More
EPS
$-6.6
FCF per Share
$20.4
Short interest
10.9%
Employees
3k
Rev per Employee
$1.5m
Show more

Is Jazz Pharmaceuticals Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

23x Buy
92%
2x Hold
8%

Analyst Opinions

25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy
92%
Hold
8%

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,087 4,087
5% 5%
100%
- Direct Costs 461 461
11% 11%
11%
3,625 3,625
4% 4%
89%
- Selling and Administrative Expenses 1,567 1,567
15% 15%
38%
- Research and Development Expense 811 811
9% 9%
20%
1,247 1,247
1% 1%
31%
- Depreciation and Amortization 633 633
3% 3%
15%
EBIT (Operating Income) EBIT 614 614
0% 0%
15%
Net Profit -405 -405
203% 203%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Jazz Pharmaceuticals Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jazz Pharmaceuticals Plc Stock News

Neutral
PRNewsWire
4 days ago
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United States For U.S. media and investors only DUBLIN , Sept. 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncolog...
Neutral
Seeking Alpha
10 days ago
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants Amal Melhem-Bertrandt Philip Johnson - Executive VP & CFO Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Thank you very much for joining us today. My name is Mohit...
Neutral
PRNewsWire
23 days ago
DUBLIN , Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2025 Wells Fargo Healthcare Conference. Company management will participate in a fireside chat on Wednesday, September 3, 2025, at 6:30 a.m.
More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Bruce Cozadd
Employees 2,800
Founded 2005
Website www.jazzpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today